Wird geladen...
Medical treatment of renal cancer: new horizons
Renal cell carcinoma (RCC) makes up 2–3% of adult cancers. The introduction of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors in the mid-2000s radically changed the management of RCC. These targeted treatments superseded immunotherapy with interleukin-2 and interferon...
Gespeichert in:
| Veröffentlicht in: | Br J Cancer |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Publishing Group
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4997553/ https://ncbi.nlm.nih.gov/pubmed/27490806 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.230 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|